

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Harry Karelis
Date of last notice	17 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Gemelli Nominees Pty Ltd <Gemelli Family A/C> - Director/shareholder
Date of change	3 February 2022
No. of securities held prior to change	49,587,680 ordinary shares 6,250,000 Class A performance rights 6,250,000 Class B performance rights
Class	Fully paid ordinary shares Class A performance rights
Number acquired	6,250,000 ordinary shares
Number disposed	6,250,000 Class A performance rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022 estimated value \$0.028 per share.
No. of securities held after change	55,837,680 ordinary shares Nil Class A performance rights 6,250,000 Class B performance rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of Class A Performance Rights pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oludare Odumosu
Date of last notice	11 August 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	3 February 2022
No. of securities held prior to change	A. 5,500,655 ordinary shares B. 17,558,328 Class A performance rights C. 17,558,328 Class B performance rights D. 5,000,000 Unquoted options exercisable at \$0.10 on or before 11 August 2023. E. 5,000,000 Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions. F. 5,000,000 Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions. G. 5,000,000 Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions. H. 5,000,000 Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	A. Ordinary shares B. Class A performance rights
Number acquired	A. 17,558,328 Ordinary shares
Number disposed	B. 17,558,328 Class A performance rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022 estimated value \$0.028 per share.
No. of securities held after change	A. 23,058,983 ordinary shares B. Nil Class A performance rights C. 17,558,328 Class B performance rights D. 5,000,000 Unquoted options exercisable at \$0.10 on or before 11 August 2023. E. 5,000,000 Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions. F. 5,000,000 Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions. G. 5,000,000 Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions. H. 5,000,000 Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of Class A Performance Rights pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lisa Gray
Date of last notice	5 October 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	3 February 2022
No. of securities held prior to change	A. 8,206,565 ordinary shares B. 58,641,228 Class A performance rights C. 58,641,228 Class B performance rights
Class	Fully paid ordinary shares Class A performance rights
Number acquired	58,641,228 ordinary shares
Number disposed	58,641,228 Class A performance rights
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022 estimated value \$0.028 per share.
No. of securities held after change	A. 66,847,793 ordinary shares B. Nil Class A performance rights C. 58,641,228 Class B performance rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of Class A Performance Rights pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Osagie Imasogie
Date of last notice	2 January 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	3 February 2022
No. of securities held prior to change	A. 16,413,065 ordinary shares B. 58,641,228 Class A performance rights C. 58,641,228 Class B performance rights
Class	Fully paid ordinary shares Class A performance rights
Number acquired	58,641,228 ordinary shares
Number disposed	58,641,228 Class A performance rights
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022 estimated value \$0.028 per share.
No. of securities held after change	A. 75,054,293 ordinary shares B. Nil Class A performance rights C. 58,641,228 Class B performance rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of Class A Performance Rights pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.